I am not approaching this from MNTA's side, but from WPI's side. Agree with Dew that there is NVS to be considered, but if WPI's internal evaluation of its legal exposure suggests a significant legal and dollar exposure, this is one way to address it. I do not currently own WPI but have traded it the last 2 months and have owned MNTA for many years and agree that it is worth more than $22/share (yet it clearly is nowhere near that now). If the market softens, $22/share will look quite attractive to many investors.
Again, simply an option for Watson for reasons listed in original post. Also would widen their biosimilar portfolio beyond AMGN relationship.
Market Data 
Markets 
AI
